Public Service Announcement: Novavax will be reporting its FQ2'22 earnings on 04 August 2022.
By now, NVAX only exported 157.01M of its stellar COVID-19 vaccine, at a time when the world is mostly inoculated or has obtained natural immunity.
We are reiterating our previous recommendation: Sell at the peak when the US FDA finally issues their approval tomorrow.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments